Prevention and Treatment
Ligand activation of the nuclear receptor PXR results in a robust TFEB-mediated autophagy induction that is predicted to remove pathological substrate accumulations in various metabolic storage diseases including alpha-1-antitrypsin deficiency or lysosomal storage diseases. These metabolic disorders can currently not sufficiently be treated.
Ligand activation of the nuclear receptor PXR results in TFEB-mediated autophagy induction that is predicted to attenuate and improve the neurodegeneration process of Huntington’s disease (HD), an otherwise currently untreatable disease.
With the blood pressure simulator (BPS), a pump was created, which allows to mimic the exact arterial pressure waveform of a heartbeat inside a laboratory/OR environment or testing facilities. The BPS can simulate every possible physiological and pathological scenario occurring inside human or animal blood vessels in vitro. Therefore, the BPS opens new possibilities in optimizing extracorporeal techniques (ECMO, ECLS), testing vascular implants (VADs, AHVs, TAVIs, stents, and delivery systems), in creating realistic settings inside laboratories (cell biology, tissue engineering, and biomechanics), and in supporting physicians to acquire new implantation techniques.
The device JURY-LITE enables the control and recording of the balloon pressure of catheters used during thromboembolectomy. JURY-LITE can especially help junior doctors to manage such a surgery in less training time. Furthermore, it can improve patient safety and potentially lowers catheter related complications.
The technology facilitates simplified and improved cancer diagnostics by combining cell analysis and in situ multiplex molecular profiling of nucleic acid and protein biomarkers on in vivo collected material, such as circulating tumor cells (CTCs).
This enables clinical decision making by monitoring disease progression and treatment response and opens up for future screening of risk groups.
Methodology to stabilize glutathione and glutathione disulfide status aiding its incorporation as routine clinical parameter
More than 1000 prospective oligo-symptomatic patients with cardiovascular risk factors are included. It consists of a collection of different sample materials of high quality and quantity with a comprehensive clinical phenotyping and long-term observation of persons and a multidisciplinary risk characterization, considering also future issues like eye or muscle changes. The cohort is based on the quality principles of the Biobank Graz that guarantees highly standardized and quality assured sample handling and storage. The linkage between clinical data and samples allows an exact allocation of clinical factors also for future examinations and treatments.
The Biobank Graz, a central service unit of the Medical University of Graz, represents an essential hub between research, medicine and economy on a national as well as international level.
Ex vivo System for Physiological Analyses of Materno-Fetal Transfer of Substances.
NGFI is a private spin-off company from the Medical University of Graz, Austria founded in 2016.
NGFI stands for a One-stop-solution provider.
NGFI provides innovative products, services, support and training for life science researchers and biotech companies. As a one-stop-solution provider, NGFI offers special tools such as novel genetically encoded fluorescent probes as well as stable cell-lines and research reagents in an affordable manner. The main aim is to support local scientists in sharing their innovative probes and tools with high quality and in a timely manner.
For details, please visit www.ngfi.eu
In case of interest please find the contact details in the box above.
We would be very happy to hear from you.